Results 11 to 20 of about 1,271,708 (300)

LINE-1 retrotransposon activation drives age-associated inflammation via cytoplasmic cDNA-STING/type I interferon signalling: therapeutic potential of reverse transcriptase inhibition

Contemporary Oncology
Retrotransposable elements are harmful at several levels, and host surveillance systems fail to consider all these elements in severe effects. The key role of retrotransposon in aging and age-associated diseases remains unclear. We summarise whether LINE-
Arshad Mehmood, Yue Zhu Xue, Habab Merghani Yassin, Mohammad Zubair, Syed Adnan Rahmat, Aftab Ahmad   +5 more
doaj   +2 more sources

Molecular monitoring of HIV-1 drug resistance in Ifakara HIV-1 Cohort, Tanzania [PDF]

, 2013
HIV-1 resistance is one of the problems affecting success of antiretroviral therapy programmes worldwide. Many studies on efficacy of ART programmes, specifically on drug resistance, have been conducted in developed countries but not in developing ...
Masimba, Pax Jessey
core   +1 more source

Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration [PDF]

, 2005
Background The genetic differences among HIV-1 subtypes may be critical to clinical management and drug resistance surveillance as antiretroviral treatment is expanded to regions of the world where diverse non-subtype-B viruses predominate.Methods and ...
Wynhoven, B, Cane, P, Holguin, A, Pedro Cahn, Maria Belen Bouzas, Africa Holguin, Luis F Brigido, Sirivichayakul, S, Anne-Mieke Vandamme, Camacho, R, Efron, B, Koya Ariyoshi, Grossman, Z, Robert W Shafer, Shafer, RW, Bouzas, MB, Brian Wynhoven, Ricardo Camacho, Jonathan N Weber, Harrigan, PR, Ariyoshi, K, Ana Patricia Carvalho, Rosangela Rodrigues, Rudich, H, Candice Pillay, Soares, MA, Katzenstein, DA, Vandamme, AM, Clarke, J, Lynn Morris, Snoeck, J, Soriano, V, Rodrigues, R, Brigido, LF, Wataru Sugiura, Praphan Phanuphak, Kantor, R, Sugiura, W, John Clarke, Jonathan M Schapiro, Rami Kantor, David A Katzenstein, Carvalho, AP, P Richard Harrigan, Patricia Cane, Phanuphak, P, Brad Efron, Pillay, D, Pillay, C, Sunee Sirivichayakul, Joke Snoeck, Cahn, P, Hagit Rudich, Schapiro, JM, Morris, L, Zehava Grossman, Amilcar Tanuri, Tanuri, A, Weber, JN, Vincent Soriano, Deenan Pillay, Marcelo A Soares   +61 more
core   +2 more sources

Reduced susceptibility of human immunodeficiency virus type 1 (HIV-1) from patients with primary HIV infection to nonnucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sites [PDF]

, 2000
Recently, significant numbers of individuals with primary human immunodeficiency virus (HN) infection have been found to harbor viral strains with reduced susceptibility to antiretroviral drugs.
Jeannette M. Whitcomb, Susan J. Little, Philip H. Keiser, Hellmann, N S, Connick, E, D'Aquila, R T, Elizabeth Connick, Douglas D. Richman, Christos J. Petropoulos, Richard T. D'Aquila, Whitcomb, J M, Joseph K. Wong, Keiser, P H, Brown, A J, Wong, J K, Richman, D D, Heather M. Precious, Eric S. Daar, Huang, W, Wei Huang, Precious, H M, Nicholas S. Hellmann, Marlynne Quigg, Quigg, M, Daar, E S, Little, S J, Andrew J. Leigh Brown, Petropoulos, C J   +27 more
core   +1 more source

Genetic basis of hypersusceptibility to protease inhibitors and low replicative capacity of human immunodeficiency virus type 1 strains in primary infection [PDF]

, 2004
The initial virus strains from as many as 12% of individuals with primary human immunodeficiency virus (HIV) infection have a 50% inhibitory concentration less than or equal to0.4-fold that of HIV type 1(NL4-3) (HIV-1(NL4-3)) to ritonavir ...
Joseph B. Margolick, Routy, JP, Susan J. Little, Frost, SDW, Leigh Brown, AJ, Connick, E, Little, SJ, Markowitz, M, Elizabeth Connick, Douglas D. Richman, Collier, AC, Richman, DD, Hellmann, NS, Brian Conway, Daar, ES, Good, B, Jacques Corbeil, Eric S. Daar, Margolick, JB, Simon D. W. Frost, Corbeil, J, Jean-Pierre Routy, Nicholas S. Hellmann, Benjamin Good, Viviana Simon, Simon, V, Ann C. Collier, Martin Markowitz, Conway, B, Andrew J. Leigh Brown   +29 more
core   +1 more source

Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda. [PDF]

, 2014
We investigated phenotypic and genotypic resistance after 2 years of first-line therapy with two HIV treatment regimens in the absence of virological ...
Awio, P., Munderi, P., Pillay, D., Ndembi, N., Nkurunziza, P., Ndembi, N, Pattery, T, Dunn, DT, van Cauwenberge, A, Gilks, C. F., Gilks, CF, Awio, P, Munderi, P, Nkurunziza, P, Kaleebu, P., Pillay, D, Goodall, RL, DART Virology Group and Trial Teams, Kaleebu, P, Goodall, R. L., Kityo, C., Dunn, D. T., Kityo, C, Pattery, T., van Cauwenberge, A.   +24 more
core   +1 more source

Phenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in patients who are chronically infected with human immunodeficiency virus type 1 [PDF]

, 2005
Increased susceptibility to the protease inhibitors saquinavir and amprenavir has been observed in human immunodeficiency virus type 1 (HIV-1) with specific mutations in protease (V82T and N88S).
Wrin, T, Ruiz, L, Petropoulos, CJ, Clotet, B, Frost, SDW, Martinez-Picado, J, Leigh Brown, AJ, Parkin, NT   +7 more
core   +1 more source

Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol. [PDF]

PLoS Pathogens, 2006
Nonnucleoside reverse transcriptase inhibitors (NNRTIs) target HIV-1 reverse transcriptase (RT) by binding to a pocket in RT that is close to, but distinct, from the DNA polymerase active site and prevent the synthesis of viral cDNA.
Anna Figueiredo, Katie L Moore, Johnson Mak, Nicolas Sluis-Cremer, Marie-Pierre de Bethune, Gilda Tachedjian   +5 more
doaj   +1 more source

A Review of Electroanalytical Techniques for Determination of Anti-HIV Drugs

International Journal of Electrochemistry, 2011
Until now after the human immunodeficiency virus (HIV) was discovered as the then tentative aetiological agent of acquired immune deficiency syndrome (AIDS), exactly 25 anti-HIV compounds have been formally approved for clinical use in the treatment of ...
Burçin Bozal, Bengi Uslu, Sibel A. Özkan   +2 more
doaj   +1 more source

The Molecular Docking of Specific Reverse Transcriptase Inhibitory Ligands onto the Molecular Model of HIV-1 Reverse Transcriptase [PDF]

Trends in Pharmaceutical Sciences
HIV-1 reverse transcriptase (RT) is a crucial enzyme in HIV replication and AIDS progression. It consists of p66 and p51 subunits and converts viral RNA into double-stranded DNA for integration into the host cell's genome.
Roohallah Yousefi
doaj   +1 more source